Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo
Clin Mol Hepatol 2021;27(3):463-473. Published online February 15, 2021
Background/Aims Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic syndrome.
Methods Subjects aged between 30 and 64 years were prospectively enrolled in the Seoul Metabolic Syndrome cohort. Serum MFG-E8 levels were measured at baseline.
Results A total of 556 subjects were included, comprising 279 women (50.2%) and 277 men (49.8%). Metabolic syndrome was diagnosed in 236 subjects (42.4%), and the mean MFG-E8 level of subjects with metabolic syndrome was significantly higher than that of subjects without metabolic syndrome (P<0.001). MFG-E8 level was significantly correlated with all metabolic syndrome components and pulse wave velocity (all P<0.05). Subjects were categorized into two groups according to the best MFG-E8 cut-off value as follows: group 1, MFG-E8 level <4,745.1 pg/mL (n=401, 72.1%); and group 2, MFG-E8 level ≥4,745.1 (n=155, 27.9%). At baseline, metabolic syndrome in group 2 was significantly more prevalent than in group 1 (63.9% vs. 34.2%, P<0.001). During median follow-up of 17 months, metabolic syndrome developed in 122 (38.1%) subjects among 320 subjects without it at baseline. The incidence of metabolic syndrome in group 2 was significantly higher than that in group 1 (55.4% vs. 34.5%, P=0.003). On multivariate analysis, MFG-E8 level ≥4,745.1 pg/mL was an independent predictor for diagnosis and development of metabolic syndrome after adjusting other factors (all P<0.05).
Conclusions Serum MFG-E8 level is a potent biomarker for the screening and prediction of metabolic syndrome.
Citations
Citations to this article as recorded by
Adipose tissue–derived MFG-E8 promotes hepatic inflammation and fibrosis through macrophage activation in a mouse MASH model Masashi Kuroda, Kazuhiro Nomura, Azumi Wada, Yui Hatano, Miki Ogawa, Saya Okamoto, Etsuko Ishikawa, Yuna Izumi-Mishima, Sonoko Yasui-Yamada, Yasuo M. Tsutsumi, Nagakatsu Harada, Rie Tsutsumi, Hiroshi Sakaue npj Metabolic Health and Disease.2026;[Epub] CrossRef
Exploring the potential of MFG-E8 in neurodegenerative diseases Dan Li, Wang Rongchun, Weihong Lu, Ying Ma Critical Reviews in Food Science and Nutrition.2025; 65(28): 5565. CrossRef
Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice Volodymyr P. Tryndyak, Rose A. Willett, Zhuolin Song, Kostiantyn Dreval, Jennifer M. Hughes Hanks, Mark I. Avigan, Fred A. Wright, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny Toxicology and Applied Pharmacology.2025; 502: 117442. CrossRef
Elevated circulating HHIP levels in patients with metabolic syndrome Jingwei Lei, Yu Yang, Yerui Lai, Dongfang Liu, Cong Wang, Weiwei Xu, Ke Li, Shengbing Li, Mengliu Yang, Ling Li Biochemical and Biophysical Research Communications.2024; 736: 150877. CrossRef
Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD Rania Dagher, Paul Fogel, Jingya Wang, David Soussan, Chia-Chien Chiang, Jennifer Kearley, Daniel Muthas, Camille Taillé, Patrick Berger, Arnaud Bourdin, Cécile Chenivesse, Sylvie Leroy, Gary Anderson, Alison A. Humbles, Michel Aubier, Roland Kolbeck, Mar PLOS ONE.2022; 17(12): e0277357. CrossRef
First
Prev
